{
  "url": "https://struct.news/briefs/veradermics-raised-its-cash-90-its-six-month-burn-got-worse",
  "title": "Veradermics raised its cash 90%. Its six-month burn got worse.",
  "summary": "The company had $319.3M in cash after equity offerings, even as operating cash flow deteriorated to negative $35.7M.",
  "published_at": "2026-08-11T20:43:33.241984+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "Veradermics, Incorporated",
    "ticker": "MANE",
    "cik": "1827635",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-11",
    "accession": "0001827635-26-000030",
    "url": "https://www.sec.gov/Archives/edgar/data/1827635/000182763526000030/mane-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2026-05-12",
    "url": "https://www.sec.gov/Archives/edgar/data/1827635/000182763526000019/mane-20260331.htm"
  },
  "reported_figures": [
    {
      "group": "MANE latest close",
      "label": "Last close",
      "value": 110.78,
      "display": "$110.78",
      "unit": "usd_per_share",
      "period": "2026-08-10",
      "detail": null,
      "source": {
        "kind": "market_data",
        "label": "Observed market close",
        "as_of": "2026-08-10"
      }
    },
    {
      "group": "MANE latest close",
      "label": "One-day move",
      "value": -3.1643356643356713,
      "display": "-3.2%",
      "unit": "percent",
      "period": "2026-08-10",
      "detail": null,
      "source": {
        "kind": "market_data",
        "label": "Observed market close",
        "as_of": "2026-08-10"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "VDPHL01 remains the main research and development spending driver, including clinical recruitment and medical education.",
      "importance": "medium",
      "evidence": "The increase of $13.8 million was primarily due to: n a $10.6 million increase in costs related to VDPHL01 primarily due to a $4.8 million increase in clinical trial marketing and recruitment costs and a $1.9 million increase in costs associated with medical educational activities.",
      "source_date": "2026-08-11"
    },
    {
      "type": "product_pipeline",
      "statement": "The company has paused VDMN and other program work to focus resources on VDPHL01.",
      "importance": "medium",
      "evidence": "These decreases were primarily attributable to the Company’s decision to pause activities related to these programs to focus efforts on VDPHL01, which resulted in decreases in chemistry, manufacturing, and control activities as well as clinical trial expenses for VDMN and other program candidates.",
      "source_date": "2026-08-11"
    }
  ],
  "related_tickers": [
    "MANE"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}